Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Few signs of a tightening regulatory climate can be found in approval numbers for 2020 – but some big decisions are still pending.
Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?
Two successful pivotal trials with vadadustat put Akebia on track to file its novel anaemia pill by year end – hot on the heels of Fibrogen.
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.